echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > CDMO Kaituo Biotech in the field of nucleic acid technology completes tens of millions of US dollars in Series A financing

    CDMO Kaituo Biotech in the field of nucleic acid technology completes tens of millions of US dollars in Series A financing

    • Last Update: 2022-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    With the advent of the era of global medical innovation, the biopharmaceutical field is experiencing the baptism of new technologies, which is expected to bring dawn to genetic diseases and rare diseases that lack effective treatments.


    On April 25, CATUG Biotechnology announced the completion of tens of millions of US dollars in Series A financing (hereinafter referred to as "CATUG Biotechnology").


    Kaituo Bio is an innovative technology company focusing on the development and application of new biopharmaceutical technologies.


    The core team of Kaituo Biotechnology comes from top international and domestic biotechnology companies and well-known domestic and foreign universities and scientific research institutions, and has rich industrial technology and management experience in the field of gene therapy and nucleic acid therapy


    Dr.


    Dr.


    Dr.


    Dr.


    Mr.


    Mr.


    Zhao Fu, CEO and founding partner of Huaxin Investment, said:

    Zhao Fu, CEO and founding partner of Huaxin Investment, said:

    The CGT field, including gene therapy, mRNA and cell therapy, is the most promising major innovation field in the biopharmaceutical industry.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.